Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GPLB Green Planet Bioengineering	$0.04	$0.06	$0.02 ▼ $0.70	$800K	3.07	3,055 shs	N/A
HEPA Hepion Pharmaceuticals	$0.06 -12.0%	$0.06	$0.03 ▼ $0.08	$652K	1.52	87,478 shs	30,072 shs
PBLA Panbela Therapeutics	$0.16	$0.19	$0.05 ▼ $0.47	$767K	1.33	16,444 shs	592 shs
PPCB Propanc Biopharma	$3.67 -37.3%	$5.87	$1.25 ▼ $145.46	$70K	2.78	642,618 shs	2.12 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GPLB Green Planet Bioengineering	0.00%	0.00%	0.00%	-63.64%	-92.00%
HEPA Hepion Pharmaceuticals	+2.86%	+7.46%	+53.19%	-20.00%	-99.80%
PBLA Panbela Therapeutics	0.00%	0.00%	-1.31%	-35.89%	-57.21%
PPCB Propanc Biopharma	+103.83%	-35.00%	+30.00%	+134.94%	+1,299,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GPLB Green Planet Bioengineering	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	1.0734 of 5 stars	0.0	5.0	0.0	0.0	2.5	0.0	0.6
PBLA Panbela Therapeutics	0.9506 of 5 stars	0.0	5.0	0.0	0.0	3.3	0.0	0.0
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
GPLB Green Planet Bioengineering	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GPLB Green Planet Bioengineering	N/A	N/A	N/A	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	$1.29 per share	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	($18.37) per share	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	($493.34) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GPLB Green Planet Bioengineering	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	-$48.93M	-$219.00	N/A	∞	N/A	N/A	-812.56%	-207.31%	N/A
PBLA Panbela Therapeutics	-$25.26M	-$71.13	N/A	∞	N/A	N/A	N/A	-302.61%	N/A
PPCB Propanc Biopharma	-$1.82M	N/A	0.00	∞	N/A	N/A	-3,652.66%	-971.09%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GPLB Green Planet Bioengineering	N/A	N/A	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GPLB Green Planet Bioengineering	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	N/A	1.30	1.30
PBLA Panbela Therapeutics	N/A	0.26	0.26
PPCB Propanc Biopharma	0.01	2.24	2.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GPLB Green Planet Bioengineering	N/A
HEPA Hepion Pharmaceuticals	17.24%
PBLA Panbela Therapeutics	4.37%
PPCB Propanc Biopharma	N/A

Insider Ownership

Company	Insider Ownership
GPLB Green Planet Bioengineering	N/A
HEPA Hepion Pharmaceuticals	0.06%
PBLA Panbela Therapeutics	0.01%
PPCB Propanc Biopharma	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GPLB Green Planet Bioengineering	1	20.01 million	N/A	Not Optionable
HEPA Hepion Pharmaceuticals	20	11.44 million	6.63 million	No Data
PBLA Panbela Therapeutics	6	4.86 million	4.86 million	Not Optionable
PPCB Propanc Biopharma	1	19,000	19,000	Not Optionable

PPCB, GPLB, PBLA, and HEPA Headlines

Recent News About These Companies

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

August 19 at 8:30 AM | globenewswire.com

Why Propanc stock Is Tumbling In Premarket Today

August 19 at 7:44 AM | msn.com

The Next Wave of Cancer Innovation: How Breakthrough Therapies Are Redefining Treatment Paradigms

August 18 at 10:15 AM | theglobeandmail.com

Propanc Biopharma Inc

August 17 at 7:11 PM | cnn.com

Propanc Biopharma opens at $4.00 in Nasdaq uplisting

August 15, 2025 | msn.com

Propanc Biopharma, Inc.: Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

August 15, 2025 | finanznachrichten.de

Propanc Biopharma prices $4M stock offering

August 15, 2025 | msn.com

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

August 14, 2025 | globenewswire.com

Propanc Biopharma 1M share Secondary; price range $4.00-$6.00

August 14, 2025 | msn.com

Propanc Biopharma Appoints New Chief Financial Officer

August 14, 2025 | msn.com

Propanc Biopharma Issues Promissory Note for Capital

June 2, 2025 | tipranks.com

Propanc Biopharma Inc (PPCB)

August 21, 2024 | investing.com

Propanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North America

August 14, 2024 | finance.yahoo.com

VTXB Vortex Brands Co.

May 29, 2024 | seekingalpha.com

Propanc Biopharma, Inc. (PPCB)

May 29, 2024 | finance.yahoo.com

Propanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent Office

April 16, 2024 | finance.yahoo.com

Propanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing

April 10, 2024 | stockhouse.com

Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing

April 8, 2024 | finance.yahoo.com

Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study

February 22, 2024 | finance.yahoo.com

Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office

January 16, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB, GPLB, PBLA, and HEPA Company Descriptions

Green Planet Bioengineering OTCMKTS:GPLB

$0.04 0.00 (0.00%)

As of 08/15/2025

Green Planet Bioengineering Co. Ltd. operates as a shell company, with the purpose of acquisition and merging with an existing business operation. The company was founded on October 30, 2006 and is headquartered in Aventura, FL.

Hepion Pharmaceuticals NASDAQ:HEPA

$0.06 -0.01 (-12.04%)

As of 02:36 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Panbela Therapeutics NASDAQ:PBLA

$0.16 0.00 (0.00%)

As of 08/18/2025 03:30 PM Eastern

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Propanc Biopharma OTCMKTS:PPCB

$3.67 -2.18 (-37.26%)

As of 04:00 PM Eastern

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time